The future possibilities for Nanogen's molecular diagnostics business broadened last week when Fisher Scientific spent $15 million to buy a 9-percent stake in the San Diego-based company.

The purchase, which makes Fisher one of Nanogen's lead investors, coincided with Fisher's $283-million acquisition of Athena Diagnostics and a plan by Fisher and Nanogen to develop and sell Athena's tests. Athena, based in Worcester, Mass., makes immunohistochemical and molecular diagnostics for neurological, nephrologic, and endocrine diseases.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.